openPR Logo
Press release

Bronchiectasis Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights By DelveInsight | SolAeroMed, Insmed, NovaBiotics Ltd, Synspira Therapeutics, Parion

08-27-2025 03:28 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Bronchiectasis Pipeline 2025: Comprehensive Clinical Trials

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Bronchiectasis pipeline constitutes 15+ key companies continuously working towards developing 15+ Bronchiectasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Bronchiectasis Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bronchiectasis Market.

The Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Bronchiectasis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Bronchiectasis treatment therapies with a considerable amount of success over the years.

*
Bronchiectasis companies working in the treatment market are SolAeroMed, Insmed, NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others, are developing therapies for the Bronchiectasis treatment

*
Emerging Bronchiectasis therapies in the different phases of clinical trials are- S1226, Brensocatib, P339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others are expected to have a significant impact on the Bronchiectasis market in the coming years.

*
In August 2025, The FDA has approved brensocatib (Brinsupri; Insmed) for the treatment of non-cystic fibrosis bronchiectasis, marking it as the first approved therapy for this patient group and the first dipeptidyl peptidase 1 (DPP1) inhibitor authorized for a neutrophil-driven disease. Brensocatib is an oral, small-molecule, reversible DPP1 inhibitor that blocks DPP1, reducing the activation of neutrophil serine proteases, which play a central role in inflammation and tissue damage in chronic lung diseases such as bronchiectasis.

*
In February 2025, The FDA assigned priority review to brensocatib, an investigational therapy for patients with non-cystic fibrosis bronchiectasis. After the new drug application was accepted, the target action date was scheduled for August 12, 2025. If approved, brensocatib would be the first approved treatment for bronchiectasis and the inaugural drug in the dipeptidyl peptidase 1 class for neutrophil-driven diseases.

*
In February 2025, Verona Pharma is a biopharmaceutical company focused on creating and commercializing innovative therapies for chronic respiratory diseases with significant unmet needs. Its first commercial product, Ohtuvayre Trademark (ensifentrine), is the first inhaled maintenance therapy for COPD that uniquely combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ensifentrine also holds promise for treating non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory disorders.

Bronchiectasis Overview

Bronchiectasis is a chronic lung condition characterized by permanent widening and damage of the airways (bronchi), leading to mucus buildup, frequent lung infections, coughing, and difficulty breathing. It often results from infections, genetic disorders like cystic fibrosis, or conditions that impair the lungs' ability to clear mucus. Early management can help reduce complications and improve quality of life.

Get a Free Sample PDF Report to know more about Bronchiectasis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/bronchiectasis-pipeline-insight [https://www.delveinsight.com/report-store/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Bronchiectasis Drugs Under Different Phases of Clinical Development Include:

*
S1226: SolAeroMed

*
Brensocatib: Insmed

*
NP339: NovaBiotics Ltd

*
Research Programme:NCFB: Synspira Therapeutics

*
Research programme: mucolytic agents: Parion Sciences

*
CHF 6333: Chiesi Farmaceutic

*
CSL787: CSL Behring

*
HSK31858: Haisco Pharmaceutical

*
S-1226: SolAeroMed Inc.

*
Benralizumab: AstraZeneca

*
Colistimethate sodium: Zambon SpA

*
BI 1291583: Boehringer Ingelheim

*
AP-PA02: Armata Pharmaceuticals

*
ARINA-1: Renovion

Bronchiectasis Route of Administration

Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Bronchiectasis Molecule Type

Bronchiectasis Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Bronchiectasis Pipeline Therapeutics Assessment

*
Bronchiectasis Assessment by Product Type

*
Bronchiectasis By Stage and Product Type

*
Bronchiectasis Assessment by Route of Administration

*
Bronchiectasis By Stage and Route of Administration

*
Bronchiectasis Assessment by Molecule Type

*
Bronchiectasis by Stage and Molecule Type

DelveInsight's Bronchiectasis Report covers around 15+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Bronchiectasis product details are provided in the report. Download the Bronchiectasis pipeline report to learn more about the emerging Bronchiectasis therapies [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Bronchiectasis Therapeutics Market include:

Key companies developing therapies for Bronchiectasis are - Zambon, Boehringer Ingelheim, SolAeroMed, Insmed Incorporated, Chiesi Farmaceutici, Renovion, Haisco Pharmaceutical, Armata Pharmaceuticals, AstraZeneca, CSL Behring, and others.

Bronchiectasis Pipeline Analysis:

The Bronchiectasis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Bronchiectasis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchiectasis Treatment.

*
Bronchiectasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchiectasis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Bronchiectasis drugs and therapies [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Bronchiectasis Pipeline Market Drivers

*
Increasing prevalence of bronchiectasis worldwide, particularly among aging populations

*
Rising awareness and improved diagnosis of the disease

*
Advancements in novel therapies targeting underlying causes and inflammation

*
Growing investment in research and development by pharmaceutical companies

*
Expansion of clinical trials exploring innovative drug candidates

Bronchiectasis Pipeline Market Barriers

*
High costs associated with drug development and clinical trials

*
Complexity of the disease with heterogeneous patient populations

*
Limited efficacy of some current therapeutic options in advanced cases

*
Stringent regulatory requirements for approval of new treatments

*
Challenges in patient recruitment for clinical trials

Scope of Bronchiectasis Pipeline Drug Insight

*
Coverage: Global

*
Key Bronchiectasis Companies: SolAeroMed, Insmed, NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others

*
Key Bronchiectasis Therapies: S1226, Brensocatib, P339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others

*
Bronchiectasis Therapeutic Assessment: Bronchiectasis current marketed and Bronchiectasis emerging therapies

*
Bronchiectasis Market Dynamics: Bronchiectasis market drivers and Bronchiectasis market barriers

Request for Sample PDF Report for Bronchiectasis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Bronchiectasis Report Introduction

2. Bronchiectasis Executive Summary

3. Bronchiectasis Overview

4. Bronchiectasis- Analytical Perspective In-depth Commercial Assessment

5. Bronchiectasis Pipeline Therapeutics

6. Bronchiectasis Late Stage Products (Phase II/III)

7. Bronchiectasis Mid Stage Products (Phase II)

8. Bronchiectasis Early Stage Products (Phase I)

9. Bronchiectasis Preclinical Stage Products

10. Bronchiectasis Therapeutics Assessment

11. Bronchiectasis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Bronchiectasis Key Companies

14. Bronchiectasis Key Products

15. Bronchiectasis Unmet Needs

16 . Bronchiectasis Market Drivers and Barriers

17. Bronchiectasis Future Perspectives and Conclusion

18. Bronchiectasis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bronchiectasis-pipeline-2025-comprehensive-clinical-trials-and-therapies-analysis-with-key-moa-and-roa-insights-by-delveinsight-solaeromed-insmed-novabiotics-ltd-synspira-therapeutics-parion]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Bronchiectasis Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights By DelveInsight | SolAeroMed, Insmed, NovaBiotics Ltd, Synspira Therapeutics, Parion here

News-ID: 4161008 • Views:

More Releases from ABNewswire

Dr. Yehuda Lehrfield of The Smile Design Center Offers Expert Tips for Long-Lasting Oral Health in Owings Mills
Dr. Yehuda Lehrfield of The Smile Design Center Offers Expert Tips for Long-Last …
Dr. Yehuda Lehrfield of The Smile Design Center in Owings Mills, MD, shares expert tips for lasting oral health, emphasizing daily care, regular checkups, and the link between oral health and overall wellness. The center also specializes in personalized Dental Implants to restore missing teeth. Owings Mills, MD - Dr. Yehuda Lehrfield, founder of The Smile Design Center, is sharing expert tips on maintaining long-lasting oral health in Owings Mills, MD.
Watch Boutique USA Expands Its Curated Collection of Luxury Watches
Watch Boutique USA Expands Its Curated Collection of Luxury Watches
Image: https://www.abnewswire.com/upload/2025/10/cc76acb0ee71bad45fea031492d4d4d7.jpg Watch Boutique USA [https://watchboutiqueusa.com/], a premier destination for discerning collectors and first-time buyers alike, has expanded its exclusive selection of authentic timepieces from the world's most prestigious brands. Operating both online and by private appointment in its Miami showroom, the boutique combines trust, authenticity, and concierge-style service to provide an unparalleled buying and selling experience. A Legacy of Luxury and Trust For over a decade, Watch Boutique USA has established a
Contentus Digital Transforms India's Content Industry with SEO-Driven, Story-Powered Writing
Contentus Digital Transforms India's Content Industry with SEO-Driven, Story-Pow …
Contentus Digital, a premier content writing agency in India, is setting new benchmarks in digital communication by offering brands powerful words that connect, engage, and convert. With a proven track record of delivering SEO-optimized content for businesses across industries, the agency is revolutionizing how companies build trust, visibility, and sales through compelling storytelling. Kolkata, India - October 2, 2025 - Contentus Digital, a premier content writing agency in India, is setting
How to Save 10% on Chicago Bulls United Center Tickets Now: Use Promo Code CITY10 at CapitalCityTickets.com
How to Save 10% on Chicago Bulls United Center Tickets Now: Use Promo Code CITY1 …
Score big savings on Chicago Bulls tickets at United Center! Learn how to save 10% instantly using promo code CITY10 at CapitalCityTickets.com. Get step-by-step tips to secure the best seats for your favorite games, compare ticket options, and enjoy exclusive online discounts. Don't miss this chance to watch the Bulls live while keeping your wallet happy-grab your discounted tickets today and cheer courtside without overspending! As the crisp fall air settles

All 5 Releases


More Releases for Bronchiectasis

Bronchiectasis Market Insights and Future Outlook
Introduction Bronchiectasis, a chronic respiratory condition characterized by abnormal widening of the bronchi, leads to persistent cough, recurrent infections, and progressive lung damage. Once considered rare, it is now increasingly diagnosed due to better imaging technologies and rising global awareness. The condition significantly impacts patient quality of life and requires lifelong management. The Bronchiectasis Market is gaining traction as healthcare systems invest in respiratory disease management, pharmaceutical companies develop advanced inhaled antibiotics,
Non-Cystic Fibrosis Bronchiectasis Market Thrives On Surging Respiratory Disease …
The Non-Cystic Fibrosis Bronchiectasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Non-Cystic Fibrosis Bronchiectasis Market? The non-cystic fibrosis bronchiectasis market has grown strongly, from $3.5 billion in 2024 to $3.74 billion in 2025 at a CAGR of 6.9%.
Key Influencer in the Non-Cystic Fibrosis Bronchiectasis Market 2025: Non-Cystic …
What industry-specific factors are fueling the growth of the non-cystic fibrosis bronchiectasis market? The rising prevalence of respiratory diseases is expected to drive the non-cystic fibrosis bronchiectasis market. Respiratory diseases, influenced by environmental pollution and lifestyle factors, are increasing. Non-cystic fibrosis bronchiectasis, a condition affecting the lungs, requires specialized treatments and interventions. A report published by the UK's Office for Health Improvement and Disparities in June 2023 showed a rise in
Transforming the Non-Cystic Fibrosis Bronchiectasis Market in 2025: Non-Cystic F …
What Is the Expected Size and Growth Rate of the Non-Cystic Fibrosis Bronchiectasis Market? The market size of non-cystic fibrosis bronchiectasis has significantly expanded in the past few years. It is projected to prosper from $3.5 billion in 2024 to $3.74 billion in 2025, indicating a compound annual growth rate (CAGR) of 6.9%. The expansion in the previous interval is due to factors like increasing occurrence and prevalence, progressive advancements
Bronchiectasis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Bronchiectasis Pipeline Insight 2024" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Bronchiectasis Research. Learn more about our innovative pipeline
Bronchiectasis Global Market Research Report 2025
Bronchiectasis Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China). Access more details about this report at: https://www.research2reports.com/report-medical-devices/bronchiectasis-market/80987 The report firstly introduced the Bronchiectasis basics: definitions, classifications, applications and market overview; product